There are 410 resources available
77TiP - A phase I/II dose escalation and dose expansion study of ozuriftamab vedotin (BA3021) alone and in combination with nivolumab in patients with advanced solid tumors including non-small cell lung cancer
Presenter: Mariam Alexander
Session: Poster Display session
78TiP - Phase Ib/IIa safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous NSCLC with/without STK11 mutations
Presenter: Rajwanth Veluswamy
Session: Poster Display session
79TiP - Progress of a phase I trial (TOTEM) of repotrectinib in combination with osimertinib in advanced, metastatic EGFR mutant NSCLC
Presenter: Andres Aguilar Hernandez
Session: Poster Display session
80TiP - High-dose aumolertinib versus osimertinib in EGFR T790M+ NSCLC patients with brain metastases (ATTACK)
Presenter: Shun Lu
Session: Poster Display session
81TiP - NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study
Presenter: Melissa Johnson
Session: Poster Display session
82TiP - A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies
Presenter: Andrew Gianoukakis
Session: Poster Display session
85P - The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on patients with stage I non-small cell lung cancer harboring sensitive EGFR mutations
Presenter: Yu Jiang
Session: Poster Display session
86P - KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma
Presenter: Daniele Marinelli
Session: Poster Display session
87P - Prognostic models of recurrence free survival in non-small cell lung cancer
Presenter: Kieran Palmer
Session: Poster Display session